Canadian Pharmacists Journal最新文献

{"title":"A future-forward influenza immunization model of care for high-risk patients in pharmacies: A Canadian consensus.","authors":"Aaron Sihota, Cameron Bonell, Brittany Buffone, Sherilyn K D Houle, Michael Kani, Josh Kim, Erica MacLean, Anas Nseir, Pavithra Ravinatarajan, Francis Richard, Tiana Tilli, Carolyn Whiskin, Victor Wong, Paul Roumeliotis","doi":"10.1177/17151635241263548","DOIUrl":"10.1177/17151635241263548","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 5","pages":"209-217"},"PeriodicalIF":1.6,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the type of pharmacy used influence medication adherence? A retrospective observational study in Aotearoa, New Zealand.","authors":"James Nind, Carlo A Marra, Shane Scahill, Charlotte Siermans, Alesha Smith","doi":"10.1177/17151635241267025","DOIUrl":"10.1177/17151635241267025","url":null,"abstract":"<p><strong>Background: </strong>Community pharmacies in New Zealand have varying ownership and operational structures. Unlike independent pharmacies, corporate and hybrid pharmacies do not charge prescription copayments.</p><p><strong>Objectives: </strong>This research aimed to determine whether people receiving free prescriptions from corporate and hybrid pharmacies (via copayment waiver) have greater medication adherence than the users of independent pharmacies.</p><p><strong>Methods: </strong>A nationwide, retrospective, observational study linked 1 year of dispensing data (1/05/2022 to 30/04/2023) from the Pharmaceutical Collection to patient enrollment data using a National Health Index number to identify demographics of different pharmacy-type users. People were assigned to a particular type of pharmacy if they collected at least 70% of their prescriptions from there; if they did not meet this threshold, they were defined as mixed users. People were classified as adherent if dispensing data showed they collected their supply of medication to cover at least 80% of the study period.</p><p><strong>Results: </strong>The sample captured 218,080 people taking at least 1 diabetes medication, with a total of 360,079 unique medications being included in the analysis. The majority, 156,893, used independent pharmacies. The type of pharmacy used was shown to be a significant predictor of adherence. Corporate and hybrid pharmacy users were 0.90 (95% CI 0.88 to 0.93) and 0.93 (95% CI 0.90 to 0.96) times as likely be adherent than the users of independent pharmacies. Mail order pharmacy users were the most likely to be adherent, whereas mixed pharmacy users were the least likely to be adherent.</p><p><strong>Conclusions: </strong>Our findings suggest that prescription copayments provided by corporate and hybrid pharmacies are not the most significant barrier to medication adherence. Further research may identify more efficient ways of improving medication adherence than removing prescription copayments for all.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 5","pages":"261-270"},"PeriodicalIF":1.6,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing hypertension detection and control through a hypertension certification program for pharmacists: A cluster randomized trial (The R_xPATH Study).","authors":"Kaitlyn E Watson, Jonathan C H Chan, Bo Pan, Yazid N Al Hamarneh, Ross T Tsuyuki","doi":"10.1177/17151635241254089","DOIUrl":"10.1177/17151635241254089","url":null,"abstract":"<p><strong>Importance: </strong>We designed an online educational program for primary care health care providers, the Hypertension Canada Professional Certification Program (HC-PCP), based upon its 2020 guidelines.</p><p><strong>Objective: </strong>The objective was to determine the effect of the HC-PCP, taken by pharmacists, on systolic blood pressure (BP) in patients with poorly controlled hypertension.</p><p><strong>Design: </strong>Stepped wedge cluster randomized trial (unit of randomization was the pharmacy).</p><p><strong>Participants: </strong>Patients with poorly controlled hypertension (BP >140/90 mmHg or >130/80 mmHg [diabetes]) in community pharmacies in Alberta, Canada, were recruited by their pharmacist.</p><p><strong>Intervention: </strong>Pharmacists completed the HC-PCP program, then provided care to their patients with poorly controlled hypertension according to what they learned in the course.</p><p><strong>Control: </strong>Pharmacists were given a copy of the Hypertension Canada guidelines and provided their usual care to their patients prior to undertaking the HC-PCP later.</p><p><strong>Main outcome and measure: </strong>The primary outcome was a difference in change in systolic BP at 3 months between groups, while the secondary outcome was patient satisfaction with using the Consultation Satisfaction Questionnaire.</p><p><strong>Results: </strong>We enrolled 890 patients from 59 pharmacies (including 104 pharmacists). Using a linear mixed-effect model with BP reduction as the dependent variable and independent variables of treatment allocation, baseline BP, site effect and patient effect, the intervention was associated with a 4.76 mmHg (95% confidence interval, 2.02-7.50, <i>p</i> < 0.0001) systolic BP reduction at 3 months. Patient satisfaction with using the Consultation Satisfaction Questionnaire was high at 75.9 (/90).</p><p><strong>Conclusion and relevance: </strong>Most educational programs are not evaluated at the patient care level. The HC-PCP taken by pharmacists resulted in a 4.76 mmHg systolic BP reduction in their patients over 3 months. This would have major implications for public health, reducing heart disease, stroke and kidney failure.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 4","pages":"190-199"},"PeriodicalIF":1.6,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pharmacist-led heart failure stewardship initiative for guideline-directed medical therapy in hospitalized patients with reduced ejection fraction.","authors":"Gemma-Dawn A MacDonald, Rochelle M Johnston, Andrew J Flewelling","doi":"10.1177/17151635241249952","DOIUrl":"10.1177/17151635241249952","url":null,"abstract":"<p><strong>Background: </strong>Heart failure with reduced ejection fraction (HFrEF) is a progressive disease with high rates of hospitalization and mortality. The Canadian Cardiovascular Society recommends treating patients with HFrEF with medications from 4 standard medication classes-this is known as guideline-directed medical therapy (GDMT). However, despite clear evidence and recommendations, GDMT agents are known to be underutilized in the HFrEF population.</p><p><strong>Objective: </strong>To determine if the implementation of a prescriber-alert stewardship tool for hospitalized patients with HFrEF will increase the frequency of GDMT prescribing with all classes during hospitalization.</p><p><strong>Methods: </strong>Utilization of GDMT in patients with HFrEF between admission and discharge pre- and post-implementation of a prescriber alert stewardship tool was compared. Patients admitted to a cardiology stepdown unit between January and April 2022 had a stewardship-alert tool placed on their chart for physician review, while those admitted during the same time frame 1 year prior did not.</p><p><strong>Results: </strong>Following the use of a prescriber alert, there was a statistically significant increase in prescribing for β-blockers (38.1% to 95.2%; <i>p</i> < 0.001), mineralocorticoid receptor antagonists (9.5% to 66.7%; <i>p</i> < 0.001) and combination GDMT (9.5% to 52.4%; <i>p</i> = 0.004) from admission to discharge. A statistically significant increase in the prescribing of β-blockers (47.6% to 76.2%; <i>p</i> = 0.004) and angiotensin-converting enzyme inhibitors (21.4% to 40.5%; <i>p</i> = 0.008) was still observed without the use of the prescriber alert.</p><p><strong>Conclusion: </strong>A pharmacist-led heart failure stewardship tool initiative increased uptake of GDMT in patients with HFrEF.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 4","pages":"181-189"},"PeriodicalIF":1.6,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autism spectrum disorder: Practice guidelines for pharmacists.","authors":"Ryma Kadi, Fady Gayed, Patrick Kauzman, Zohal Amam Ali, Iliya Dmitriev, Vanessa Mikhael, Rawane Ghabi, Jessica Hamamji, Sandra Jabbour, Monique Mrchak, Natalie Guirguis, Marie-Elaine Metras, Laurent Becciolini, Faye-Marie Vassel, Andreas Gutzeit, Jeanne Cresson, Johannes M Froehlich, Tamsin Higgs, Marie-Michele Dufour, Simon Matoori","doi":"10.1177/17151635241228495","DOIUrl":"10.1177/17151635241228495","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 2","pages":"58-65"},"PeriodicalIF":1.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perceptions of a pharmacist-led interprofessional chronic pain clinic.","authors":"Derek Jorgenson, Katelyn Halpape, Michael Siton","doi":"10.1177/17151635241226944","DOIUrl":"10.1177/17151635241226944","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 2","pages":"66-69"},"PeriodicalIF":1.5,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating rare disease medications: A pharmacist's primer.","authors":"Ahmad Shakeri, Yasmin Abdul Aziz, Mina Tadrous","doi":"10.1177/17151635241228274","DOIUrl":"10.1177/17151635241228274","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 2","pages":"50-52"},"PeriodicalIF":1.5,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Buprenorphine-naloxone in chronic pain: Overcoming stigma for safer opioid management.","authors":"Naomi Steenhof, Karen Ng","doi":"10.1177/17151635231214508","DOIUrl":"10.1177/17151635231214508","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 1","pages":"7-9"},"PeriodicalIF":1.6,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health professional perceptions of a pharmacist-led interprofessional chronic pain clinic.","authors":"Derek Jorgenson, Katelyn Halpape, Michael Siton","doi":"10.1177/17151635231213326","DOIUrl":"10.1177/17151635231213326","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"157 1","pages":"25-29"},"PeriodicalIF":1.6,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INvestigation of the impact of a Pharmacist in a Hospital At Home Care Team (IN PHACT)","authors":"Morgan E. Patrick, Curtis K. Harder, Sean P. Spina","doi":"10.1177/17151635231200233","DOIUrl":"https://doi.org/10.1177/17151635231200233","url":null,"abstract":"Background: In November 2020, Island Health, with the support of the British Columbia Ministry of Health, introduced the Hospital at Home (HaH) care model at Victoria General Hospital in Victoria, British Columbia. Given the acuity of the patients anticipated to receive care through this model, questions arose regarding how the delivery of clinical pharmacy services on which inpatients rely on could be included. With limited supporting evidence for the inclusion of a clinical pharmacist, Island Health launched the HaH program with 2 clinical pharmacists who provide services 7 days a week during daytime hours. The aim of this study is to assess the impact of the HaH pharmacist on patient care, from the perspective of the pharmacists serving in this role, patients, caregivers and program stakeholders. Methods: This prospective, observational mixed-methods study was conducted from December 2021 to March 2022. Data collection involved the HaH pharmacist documenting daily clinical activities and resolving drug therapy problems, patients and caregivers completing a 4-question postdischarge phone survey and program stakeholders completing a 9-question online survey and an optional 7-question interview. Results and Interpretation: It was found that one of the most significant roles the pharmacist plays is in identifying indications for medication therapy and making recommendations to initiate therapy where there is an absence. There was high congruence between patient, caregiver and stakeholder perceptions that the HaH pharmacist positively affects patient care within the Island Health model. Conclusion: This study provides support for the integration of a dedicated clinical pharmacist in the HaH care model.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136382258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}